¼¼°èÀÇ Ç÷°ü³» ½ºÅÙÆ® ½ÃÀå
Intravascular Stents
»óǰÄÚµå : 1774955
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 462 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,180,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,541,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Ç÷°ü³» ½ºÅÙÆ® ¼¼°è ½ÃÀåÀº 2030³â±îÁö 408¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 280¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Ç÷°ü³» ½ºÅÙÆ® ¼¼°è ½ÃÀåÀº 2024-2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 6.5%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 408¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¾à¹° ¿ëÃâ ½ºÅÙÆ®´Â CAGR 6.6%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 265¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÏ¹Ý ±Ý¼Ó ½ºÅÙÆ® ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ CAGR·Î 6.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 76¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 10.2%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ Ç÷°ü³» ½ºÅÙÆ® ½ÃÀåÀº 2024³â¿¡ 76¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 84¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 10.2%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 3.2%¿Í 6.3%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 4.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Ç÷°ü³» ½ºÅÙÆ® ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Ç÷°ü³» ½ºÅÙÆ®°¡ ½ÉÇ÷°ü Ä¡·áÀÇ ÁøÈ­ÀÇ Á߽ɿ¡ ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

Ç÷°ü³» ½ºÅÙÆ®´Â °ü»óµ¿¸ÆÁúȯ(CAD) ¹× ¸»ÃÊÇ÷°üÁúȯ °ü¸®¿¡¼­ ¼ö¼úÀû ÁßÀç¿¡ ´ëÇÑ ÃÖ¼Òħ½ÀÀû ´ë¾ÈÀ¸·Î °¢±¤¹Þ°í ÀÖ½À´Ï´Ù. ÀÌ ÀÛÀº ±×¹°¸Á ¸ð¾çÀÇ °ü ¸ð¾çÀÇ ±â±¸´Â Ç÷°üÀ» ÁöÁöÇϰí Ç÷°ü¼ºÇü¼ú ÈÄ µ¿¸ÆÀÇ °³Å뼺À» À¯ÁöÇϱâ À§ÇØ »ç¿ëµË´Ï´Ù. ½ÉÇ÷°ü°è ÁúȯÀº ¿©ÀüÈ÷ Àü ¼¼°è »ç¸Á¿øÀÎ 1À§·Î, È¿°úÀûÀÌ°í ³»±¸¼º ÀÖ´Â Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Ç÷°ü³» ½ºÅÙÆ® ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ±â¼ú Çõ½Å, »ýȰ½À°üº´ À¯º´·ü Áõ°¡, ¸»ÃÊÇ÷°ü ¹× ½Å°æÇ÷°ü ÀûÀÀÁõ È®´ë µîÀÌ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

Áß¿äÇÑ Æ®·»µå´Â º£¾î¸ÞÅ»½ºÅÙÆ®(BMS)¿¡¼­ ¾à¹° ¿ëÃ⽺ÅÙÆ®(DES)¿Í »ýüÈí¼ö¼º½ºÅÙÆ®(BRS)·ÎÀÇ ÀüȯÀÔ´Ï´Ù. ÀçÇùÂøÀ» ¿¹¹æÇÏ´Â Ç×Áõ½ÄÁ¦¸¦ ¹æÃâÇÏ´Â DES´Â ½ºÅÙÆ® ³» ÀçÇùÂø ¹ß»ý·üÀÌ ³·°í Àå±â ¿¹Èİ¡ °³¼±µÇ¾î BMS¸¦ ´ëüÇϰí ÀÖ½À´Ï´Ù. »ýüÈí¼ö¼º ½ºÅÙÆ®´Â ¾ÆÁ÷ µµÀÔ Ãʱ⠴ܰ迡 ÀÖÁö¸¸, ½Ã°£ÀÌ Áö³ª¸é ³ì¾Æ ¾ø¾îÁö´Â ÀϽÃÀûÀÎ ¹ßÆÇÀ» Á¦°øÇÔÀ¸·Î½á Â÷¼¼´ë Ç÷°ü ÀÎÅͺ¥¼Ç ±â¼úÀ» ´ëÇ¥ÇÕ´Ï´Ù. ¶ÇÇÑ, ½ºÅÙÆ® Àü´Þ ½Ã½ºÅÛ, ÄÚÆÃ ±â¼ú, ¸ÂÃãÇü ½ºÅÙÆ® »çÀÌ¡ÀÇ ¹ßÀüÀ¸·Î ½Ã¼ú ¼º°ø·üÀÌ Çâ»óµÇ¾î º¸´Ù ±¤¹üÀ§ÇÑ Ç÷°ü Áúȯ¿¡ ´ëÇÑ »ç¿ëÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù.

Àç·á¿Í µðÀÚÀÎÀÇ Çõ½ÅÀÌ ÀÓ»ó °á°ú¸¦ ¾î¶»°Ô °³¼±Çϰí Àִ°¡?

Ç÷°ü³» ½ºÅÙÆ®ÀÇ ÁøÈ­´Â Àç·á °úÇаú ÀåÄ¡ °øÇÐÀÇ ±Þ¼ÓÇÑ ¹ßÀü¿¡ ÀÇÇØ ÃßÁøµÇ°í ÀÖ½À´Ï´Ù. ½ºÅÙÆ® ±¸Á¶¿¡ ÄÚ¹ßÆ® Å©·Ò ÇÕ±ÝÀ̳ª ¹é±Ý Å©·Ò ÇÕ±ÝÀ» »ç¿ëÇÔÀ¸·Î½á ¹Ý°æ ¹æÇâÀÇ °­µµ, ¿µ»ó ÇÏ¿¡¼­ÀÇ °¡½Ã¼º, ±¼°î¼ºÀÌ Çâ»óµÇ¾î ±¼°îÁø Ç÷°üÀÇ ÇØºÎÇÐÀû ±¸Á¶¸¦ Ž»öÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ä¼Ò·Î ÀÛ¿ëÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Àç·á´Â ¶ÇÇÑ ´õ ¾ãÀº ÁöÁö´ë¸¦ Çã¿ëÇϰí, Ç÷°ü ¿Ü»óÀ» ÁÙÀ̰í, ³»ÇÇÀÇ Ä¡À¯¸¦ ÃËÁøÇÕ´Ï´Ù. ÀÌ¿Í ÇÔ²² Â÷¼¼´ë DES Ç÷§ÆûÀº ¾à¹° ¹æÃâ ÈÄ ºÐÇØµÇ´Â »ýÈí¼ö¼º Æú¸®¸Ó ÄÚÆÃÀ» Ư¡À¸·Î ÇÏ¿©, ÆÐ¸Ó³ÍÆ® Æú¸®¸Ó¿¡ µû¸¥ Àå±âÀûÀÎ ¿°Áõ°ú Ç÷Àü Çü¼ºÀÇ À§ÇèÀ» ÃÖ¼ÒÈ­ÇÕ´Ï´Ù.

½Å°æÇ÷°ü ¹× ¸»ÃÊÇ÷°ü ½ÃÀå¿¡¼­´Â ´ÏƼ³î(´ÏÄÌ-ƼŸ´½ ÇÕ±Ý)·Î ¸¸µç ÀÚ°¡ È®ÀåÇü ½ºÅÙÆ®°¡ ÃÊź¼º Ư¼º°ú Ç÷°ü µ¿¿ªÇп¡ ÀûÀÀÇÏ´Â ´É·ÂÀ¸·Î Àα⸦ ²ø°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Ç÷°ü³» ÃÊÀ½ÆÄ(IVUS) ¹× ±¤°£¼·´ÜÃþÃÔ¿µ(OCT)°ú °°Àº ¿µ»ó ±â¼úÀÇ ÅëÇÕÀ¸·Î ½ºÅÙÆ® »ðÀÔÀÇ Á¤È®µµ°¡ Çâ»óµÇ¾î ÃÖÀûÀÇ ¹èÄ¡¿Í È®ÀåÀ» º¸ÀåÇÕ´Ï´Ù. ³ª³ë±â¼ú ±â¹ÝÀÇ ÄÚÆÃ ¹× À¯ÀüÀÚ ¿ëÃâ ½ºÅÙÆ®¿¡ ´ëÇÑ ¿¬±¸µµ ÁøÇà ÁßÀ̸ç, ¾à¹°Àü´Þ È¿À²À» °³¼±ÇÏ°í ½ºÅÙÆ® ¸»±â Ç÷ÀüÁõ µîÀÇ ÇѰ踦 ±Øº¹Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ÃÖ¼Òħ½ÀÀû Ç÷°ü Ä¡·áÀÇ °¡´É¼ºÀ» ÀçÁ¤ÀÇÇϰí ÀÖ½À´Ï´Ù.

¾î¶² Ä¡·á ºÐ¾ß¿Í »ç¿ë »ç·Ê°¡ äÅÃÀ» ÁÖµµÇϰí Àִ°¡?

°ü»óµ¿¸Æ ÁúȯÀº ¿©ÀüÈ÷ Ç÷°ü³» ½ºÅÙÆ® »ç¿ëÀÇ °¡Àå Å« ºÎºÐÀ» Â÷ÁöÇϰí ÀÖÀ¸¸ç, Àü ¼¼°è ½Ã¼úÀÇ ´ëºÎºÐÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÇãÇ÷¼º ½ÉÀåÁúȯÀÇ È®»êÀº ´ç´¢º´, ºñ¸¸, °íÇ÷¾ÐÀÇ À¯º´·ü Áõ°¡¿Í ÇÔ²² ¼±Áø±¹ ½ÃÀå°ú ½ÅÈï±¹ ½ÃÀå ¸ðµÎ¿¡¼­ Ä¡·á °Ç¼ö¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. Ç÷°ü³» ½ºÅÙÆ®´Â º¸´Ù À¯¿¬Çϰí Àü´ÞÇϱ⠽¬¿î ½ºÅÙÆ® Ç÷§ÆûÀ¸·Î ÀÎÇØ ºÐÁö, ¸¸¼º ¿ÏÀüÆó»ö, ±æ°í ³ÐÀº ¹Ì¸¸¼º º´º¯°ú °°Àº º¹ÀâÇÑ º´º¯¿¡ ´õ ¸¹ÀÌ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Çõ½ÅÀ» ÅëÇØ ÀÎÅͺ¥¼Ç ½ÉÀåÀü¹®ÀÇ´Â ÀÌÀü¿¡´Â ½ºÅÙÆ® »ðÀÔ¿¡ ÀûÇÕÇÏÁö ¾Ê¾Ò´ø °íÀ§Ç豺 ȯÀÚ±º±îÁö Ä¡·á¸¦ È®´ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù.

°ü»óµ¿¸Æ¿¡ ´ëÇÑ Àû¿ë»Ó¸¸ ¾Æ´Ï¶ó, ¸»Ãʵ¿¸ÆÁúȯ(PAD)Àº ƯÈ÷ °í·ÉÈ­µÈ ȯÀÚÃþ¿¡¼­ ÁÖ¸ñµµ°¡ ³ô¾ÆÁö°í ÀÖ´Â ºÐ¾ßÀÔ´Ï´Ù. ÀÚ°¡ È®ÀåÇü ½ºÅÙÆ®´Â ´ëÅð ½½¿Í µ¿¸Æ°ú Àå°ñ µ¿¸Æ¿¡ ³Î¸® »ç¿ëµÇ°í ÀÖÀ¸¸ç, »ý¿ªÇÐÀû ½ºÆ®·¹½º°¡ Å« Ç÷°ü¿¡¼­ Àå±âÀûÀÎ °³Å뼺À» Á¦°øÇÕ´Ï´Ù. ½Å°æÇ÷°ü¿ë ½ºÅÙÆ®´Â ³úµ¿¸Æ·ù ¹× ÇãÇ÷¼º ³úÁ¹Áß Ä¡·á, ƯÈ÷ Ç÷ÀüÁ¦°Å ±â±â¿Í ÇÔ²² »ç¿ëÇÏ´Â °æ¿ì°¡ ¸¹¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌó·³ °ü»óµ¿¸Æ, ¸»ÃÊ, ½Å°æÇ÷°ü °¢ ¿µ¿ª¿¡¼­ »ç¿ë »ç·Ê°¡ È®´ëµÊ¿¡ µû¶ó ´ëÀÀ °¡´ÉÇÑ ½ÃÀå ±Ô¸ð°¡ È®´ëµÉ »Ó¸¸ ¾Æ´Ï¶ó, ´Ù¾çÇÑ Ç÷°ü ȯ°æ¿¡ ¸Â´Â Ư¼öÇÑ µðÀÚÀÎÀÇ ½ºÅÙÆ®¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

ÀÓ»óÀû, ±â¼úÀû, Áö¿ªÀû Ãø¸é¿¡¼­ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

Ç÷°ü³» ½ºÅÙÆ® ½ÃÀåÀÇ ¼ºÀåÀº ÀÓ»ó ¼ö¿ä, ±â¼ú Çõ½Å ÆÄÀÌÇÁ¶óÀÎ, ÀÇ·á ÀÎÇÁ¶ó È®Àå°ú °ü·ÃµÈ ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. °¡Àå Å« ¿øµ¿·Â Áß Çϳª´Â ¼¼°è Àα¸ÀÇ °í·ÉÈ­¿Í ÀÌ¿¡ µû¸¥ ½ÉÇ÷°ü ¹× ¸»ÃÊÇ÷°ü ÁúȯÀÇ Áõ°¡ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Àα¸Åë°èÇÐÀû º¯È­´Â ƯÈ÷ ¿Ü·¡ ȯÀÚ ¹× ¿Ü·¡ Áø·á ÇöÀå¿¡¼­ ½ºÅÙÆ®¿Í °°Àº ÃÖ¼Òħ½ÀÀûÀ̰í È¿°úÀûÀÎ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¼ö¿ä¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡ Àü ¼¼°è ÇコÄÉ¾î »ê¾÷Àº °¡Ä¡ Áß½ÉÀ¸·Î ÀüȯÇϰí ÀÖÀ¸¸ç, Àç¿øÀϼö¸¦ ÃÖ¼ÒÈ­Çϰí ÇÕº´Áõ ¹ß»ý·üÀ» ³·Ã߸ç Àå±âÀûÀÎ °á°ú¸¦ °³¼±ÇÏ´Â Ä¡·á¹ýÀ» ¼±È£Çϰí ÀÖ½À´Ï´Ù.

¶Ç ´Ù¸¥ Áß¿äÇÑ ¼ºÀå ¿äÀÎÀº ÀÇ·á±â±â ¾÷üµéÀÇ Â÷¼¼´ë ½ºÅÙÆ® Ç÷§Æû¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¬±¸°³¹ß ÅõÀÚÀÔ´Ï´Ù. ¾à¹° ¿ëÃâ ±â¼ú, »ýüÈí¼ö¼º ¼ÒÀç, AI¸¦ ÅëÇÕÇÑ ½ºÅÙÆ® °èȹ µµ±¸¿¡ ÁýÁßÇÔÀ¸·Î½á °æÀïÀÌ Ä¡¿­ÇÑ ½ÃÀå¿¡¼­ Â÷º°È­¸¦ µµ¸ðÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ Áö¿ªÀÇ ÀÇ·á Á¢±Ù¼º ¹× Ä«Å×ÅÍ °Ë»ç½ÇÀÇ ±Þ¼ÓÇÑ È®ÀåÀº ½Ã¼ú °Ç¼ö Áõ°¡¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. °³¼±µÈ Áø·áºñ º¸»ó, À¯¸®ÇÑ ÀÓ»ó °¡À̵å¶óÀÎ, ÀÇ»ç ±³À° ÇÁ·Î±×·¥ µîÀÌ ÀÌ Áö¿ª¿¡¼­ÀÇ Ã¤ÅÃÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÓ»óÀû, ±â¼úÀû, ±¸Á¶Àû ÃËÁø¿äÀÎÀÇ À¶ÇÕÀº ¼¼°è Ç÷°ü³» ½ºÅÙÆ® ½ÃÀåÀÇ Áö¼ÓÀûÀÌ°í °­·ÂÇÑ ¼ºÀåÀÇ ¹ßÆÇÀ» ¸¶·ÃÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

À¯Çü(¾à¹° ¿ëÃâ, º£¾î¸ÞÅ», »ýüÈí¼ö¼º), Á¦°ø ¹æ½Ä(ÀÚ°¡È®ÀåÇü, dz¼±È®ÀåÇü), Á¦Ç° À¯Çü(°ü»óµ¿¸Æ, ¸»ÃÊ, ½Å°æÇ÷°ü), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø¡¤½ÉÀå ¼¾ÅÍ, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ±âŸ)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× ¾÷°è °íÀ¯ÀÇ SLMÀ» Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹üÀ» µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû, °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Intravascular Stents Market to Reach US$40.8 Billion by 2030

The global market for Intravascular Stents estimated at US$28.0 Billion in the year 2024, is expected to reach US$40.8 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2024-2030. Drug Eluting Stents, one of the segments analyzed in the report, is expected to record a 6.6% CAGR and reach US$26.5 Billion by the end of the analysis period. Growth in the Bare Metal Stents segment is estimated at 6.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.6 Billion While China is Forecast to Grow at 10.2% CAGR

The Intravascular Stents market in the U.S. is estimated at US$7.6 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.4 Billion by the year 2030 trailing a CAGR of 10.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.3% CAGR.

Global Intravascular Stents Market - Key Trends & Drivers Summarized

Why Are Intravascular Stents Central to the Evolution of Cardiovascular Treatment?

Intravascular stents have become a cornerstone in the management of coronary artery disease (CAD) and peripheral vascular disorders, offering a minimally invasive alternative to surgical interventions. These small mesh-like tubular devices are used to support blood vessels and maintain arterial patency after angioplasty procedures. With cardiovascular diseases remaining the leading cause of death globally, the demand for effective and durable treatment options is driving the expansion of the intravascular stents market. Technological innovation, growing prevalence of lifestyle diseases, and expanded indications in peripheral and neurovascular applications are among the key contributors to market growth.

A significant trend is the transition from bare-metal stents (BMS) to drug-eluting stents (DES) and bioresorbable scaffolds (BRS). DES, which release antiproliferative drugs to prevent restenosis, have largely replaced BMS due to their lower rate of in-stent restenosis and improved long-term outcomes. Bioresorbable stents, although still in early phases of adoption, represent the next generation of vascular intervention technologies by offering temporary scaffolding that dissolves over time. Additionally, advancements in stent delivery systems, coating technologies, and personalized stent sizing are improving procedural success rates and expanding usage across a broader range of vascular conditions.

How Are Innovations in Materials and Design Elevating Clinical Outcomes?

The evolution of intravascular stents is being driven by rapid progress in materials science and device engineering. The use of cobalt-chromium and platinum-chromium alloys in stent construction has enhanced radial strength, visibility under imaging, and flexibility-critical for navigating tortuous vascular anatomies. These materials also allow thinner struts, which reduce vessel trauma and promote faster endothelial healing. In parallel, new-generation DES platforms feature bioabsorbable polymer coatings that degrade after drug release, minimizing long-term inflammation and thrombogenic risk associated with permanent polymers.

In neurovascular and peripheral vascular markets, self-expanding stents made of nitinol (nickel-titanium alloy) are gaining traction due to their superelastic properties and ability to adapt to vessel dynamics. Moreover, the integration of imaging technologies such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT) is enhancing stent placement accuracy, ensuring optimal apposition and expansion. Research into nanotechnology-based coatings and gene-eluting stents is also underway, aiming to improve drug delivery efficiency and address limitations like late stent thrombosis. These advances are redefining what’s possible in minimally invasive vascular therapy.

Which Therapeutic Segments and Use Cases Are Driving Adoption?

Coronary artery disease remains the largest segment for intravascular stent use, accounting for the bulk of global procedures. The widespread prevalence of ischemic heart disease, combined with the rising incidence of diabetes, obesity, and hypertension, is fueling procedural volumes in both developed and emerging markets. Intravascular stents are increasingly being used in complex lesions, such as bifurcations, chronic total occlusions, and long diffuse lesions, thanks to more flexible and deliverable stent platforms. These innovations allow interventional cardiologists to expand treatment to high-risk patient groups that were previously unsuitable for stenting.

Beyond coronary applications, peripheral artery disease (PAD) is a growing area of focus, particularly in aging populations. Self-expanding stents are widely used in the femoropopliteal and iliac arteries, providing long-term patency in vessels subject to high biomechanical stress. Neurovascular stents are also seeing increased deployment in the treatment of cerebral aneurysms and ischemic stroke, especially in conjunction with thrombectomy devices. These expanded use cases across coronary, peripheral, and neurovascular domains are not only increasing total addressable market size but also driving demand for specialized stent designs tailored to different vascular environments.

What’s Fueling the Market Growth Across Clinical, Technological, and Regional Dimensions?

The growth in the intravascular stents market is driven by several factors related to clinical demand, innovation pipelines, and expanding healthcare infrastructure. One of the most significant drivers is the aging global population and the associated rise in cardiovascular and peripheral vascular conditions. This demographic shift is creating sustained demand for less invasive, high-efficacy treatment solutions like stents, particularly in outpatient and ambulatory care settings. Concurrently, the global healthcare industry is moving toward value-based care, favoring interventions that minimize hospital stays, reduce complication rates, and improve long-term outcomes-attributes that intravascular stents are well-positioned to deliver.

Another key growth factor is the ongoing R&D investment by medical device companies in next-generation stent platforms. The focus on drug-eluting technology, bioresorbable materials, and AI-integrated stent planning tools is fostering differentiation in an otherwise competitive market. Additionally, the rapid expansion of healthcare access and catheterization labs in Asia-Pacific, Latin America, and the Middle East is contributing to higher procedural volumes. Reimbursement improvements, favorable clinical guidelines, and physician training programs are further supporting adoption in these regions. The convergence of these clinical, technological, and structural drivers is setting the stage for sustained and robust growth in the global intravascular stents market.

SCOPE OF STUDY:

The report analyzes the Intravascular Stents market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Drug Eluting Stents, Bare Metal Stents, Bioabsorbable Stents); Delivery Mode (Self-expanding Stents, Balloon-expandable Stents); Product Type (Coronary Stents, Peripheral Stents, Neurovascular Stents); End-Use (Hospitals & Cardiac Centers, Ambulatory Surgery Centers, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â